Inverness Medical Innovations Inc. and BG Medicine Inc. ink a deal to develop a test for the galectin-3 heart failure biomarker.
BG Medicine Inc. and Inverness Medical Innovations Inc. (NYSE:IMA) inked a deal to develop and commercialize a galectin-3 test for heart failure.
The Waltham, Mass.-based companies said Inverness will develop the test for its Triage Meter Pro testing platform in collaboration with BG, which will support the effort and its regulatory filings, according to a press release.
BG Medicine Inc. is touting the results of a peer-reviewed study of its test for the galectin-3 biomarker, which it claims can help predict the risk of dying from a heart attack.
BG Medicine Inc. said its galectin-3 test to predict the risk of dying from heart failure did well in a controlled, peer-reviewed clinical trial published in the journal Clinical Research in Cardiology.
The report summarizing the study, "Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study," showed that the Waltham, Mass-based company's test for the galectin-3 biomarker was "a significant predictor of mortality risk," according to a press release. The trial followed 232 patients with an average age of 71 (plus or minus a decade), 72 percent of whom were male. After six-and-a-half years, 98 of the patients, or 37.4 percent, had died.
Static and Dynamic testing systems for materials, components, and devices. Systems range from 50 grams to 600kN of force capacity in tension, compression, torsion, and more.
Provides grips, fixtures, heating and cooling systems, and fluid baths.